NetworkNewsBreaks – TC BioPharm Holdings PLC (NA
Post# of 10
(Total Views: 52)
Posted On: 10/03/2024 5:05:33 PM
NetworkNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP), Carnegie Mellon University Partner to Potentially Revolutionize Donor Selection, Matching Processes with AI
TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, today announced its sponsored research agreement with Carnegie Mellon University. Under the agreement, TC BioPharm is partnering with Dr. Wei Wu, a faculty member in the Ray and Stephanie Lane Computational Biology Department within the university’s School of Computer Science, and her lab to explore the potential use of artificial intelligence (“AI”) to enhance the donor selection and matching processes.
“Dr. Wu and her laboratory are helping us tackle another ‘big problem’ with this endeavor, which has the potential to revolutionize both the donor selection and matching processes. An issue the cell therapy industry faces as a whole is donor variability as well as how to more accurately predict outcomes and responses between donors and patients. Finding a solution for how to select the best donors for allogeneic cell therapies to generate the best product, and also how to match the best cell therapy and donor to the best patient beyond the current HLA matching process, represents a massive opportunity from a market perspective and also would have far-reaching applications for CDMOs and other industry players,” said Bryan Kobel, CEO of TC BioPharm.
NOTE TO INVESTORS: The latest news and updates relating to TCBP are available in the company’s newsroom at https://nnw.fm/TCBP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, today announced its sponsored research agreement with Carnegie Mellon University. Under the agreement, TC BioPharm is partnering with Dr. Wei Wu, a faculty member in the Ray and Stephanie Lane Computational Biology Department within the university’s School of Computer Science, and her lab to explore the potential use of artificial intelligence (“AI”) to enhance the donor selection and matching processes.
“Dr. Wu and her laboratory are helping us tackle another ‘big problem’ with this endeavor, which has the potential to revolutionize both the donor selection and matching processes. An issue the cell therapy industry faces as a whole is donor variability as well as how to more accurately predict outcomes and responses between donors and patients. Finding a solution for how to select the best donors for allogeneic cell therapies to generate the best product, and also how to match the best cell therapy and donor to the best patient beyond the current HLA matching process, represents a massive opportunity from a market perspective and also would have far-reaching applications for CDMOs and other industry players,” said Bryan Kobel, CEO of TC BioPharm.
NOTE TO INVESTORS: The latest news and updates relating to TCBP are available in the company’s newsroom at https://nnw.fm/TCBP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)TC BioPharm Holdings Plc (TCBP) Stock Research Links
Scroll down for more posts ▼